GleamWall
中文EN

AMRX Amneal Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%

Margins

Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—

Returns

ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x

Leverage & solvency

Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$862.68M$796.20M$722.52M$814.32M$784.51M$724.51M$695.42M$730.52M
Cost of revenue$528.57M$461.69M$402.41M$517.13M$510.54M$438.25M$439.53M$467.64M
Gross profit$334.12M$334.51M$320.11M$297.19M$273.97M$286.25M$255.89M$262.87M
R&D expense$68.37M$39.02M$38.38M$34.82M$63.35M$47.96M$40.04M$54.27M
SG&A expense$139.65M$148.72M$138.86M$146.46M$137.81M$124.27M$118.29M$128.69M
Operating income$95.42M$129.77M$141.77M$112.03M$70.34M$111.37M$100.35M$75.79M
Pretax income$15.06M$70.99M$80.18M$55.23M-$5.22M$51.71M$37.49M-$15.32M
Income tax$2.75M$1.38M$2.18M$5.66M-$23.36M$16.10M$12.87M$5.42M
Net income-$21.70M$57.66M$62.26M$35.08M$2.37M$22.42M$12.20M-$31.08M
EBITDA$110.11M——$125.63M$84.84M———
EPS (basic)-0.060.180.20—0.010.070.04—
EPS (diluted)-0.060.180.19—0.010.070.04—
Weighted avg. shares (diluted)335.73M328.10M328.93M—324.75M322.36M323.96M—
Balance sheet
Cash & equivalents$157.40M$127.64M$197.66M$282.03M$201.25M$71.54M$59.19M$118.42M
Inventory$707.96M$677.95M$641.62M$606.30M$614.50M$608.97M$601.43M$612.45M
Current assets$2.10B$1.95B$1.80B$1.91B$1.84B$1.58B$1.51B$1.59B
PP&E, net$572.63M$456.88M$444.61M$442.95M$434.99M$440.33M$427.23M$424.91M
Goodwill$772.47M$593.50M$593.80M$595.47M$595.95M$597.41M$597.50M$597.44M
Intangibles$1.55B$587.83M$534.87M$563.50M$587.94M$649.55M$689.14M$732.38M
Total assets$5.27B$3.78B$3.54B$3.68B$3.60B$3.42B$3.37B$3.50B
Current liabilities$1.12B$883.19M$728.05M$881.63M$862.11M$1.11B$1.08B$1.13B
Short-term debt$23.93M$5.96M$6.20M$6.76M$7.20M$31.18M$31.79M$224.21M
Long-term debt$2.92B$2.56B$2.57B$2.57B$2.57B$2.15B$2.15B$2.16B
Total debt$2.94B$2.57B$2.57B$2.57B$2.57B$2.18B$2.19B$2.39B
Total liabilities$4.63B$3.66B$3.50B$3.67B$3.64B$3.47B$3.42B$3.55B
Shareholders' equity$531.26M$33.02M-$45.41M-$70.79M-$109.46M-$112.12M-$131.67M-$109.27M
Net debt$2.78B$2.44B$2.37B$2.29B$2.37B$2.11B$2.13B$2.27B
Cash flow statement
Operating cash flow$98.30M-$21.24M-$26.74M$130.31M$118.45M$83.82M$7.41M$118.08M
Capital expenditure$31.79M$30.70M$8.18M$21.77M$12.30M$22.83M$13.16M$15.15M
Free cash flow$66.51M-$51.94M-$34.92M$108.54M$106.15M$60.99M-$5.75M$102.92M
Investing cash flow-$472.23M-$122.74M-$21.71M-$45.45M-$22.46M-$26.55M-$17.80M-$16.06M
Financing cash flow$415.19M$79.36M-$59.05M-$10.12M$59.44M-$41.69M-$39.17M-$61.20M
Depreciation & amortization$14.70M——$13.60M$14.50M———
Stock-based compensation$10.52M$10.39M$8.82M$8.20M$8.22M$8.27M$7.26M$7.21M

Free plan shows the latest 8 periods; Pro shows all 40 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.